Press Releases
Stay up to date with press releases covering announcements, company news, product launches, and business updates.
Publish your press release
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
GlobeNewswire, Inc.
TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules...
CRO Marketplace LLC Launches Digital Platform to Transform How Life Science Professionals Connect with Service Providers
EIN Presswire
New digital B2B platform simplifies how life science professionals and service providers connect, promote their expertise, and build strategic partnerships.
Global Health Journal anchored the first meeting of the 4th editorial board at the People’s Medical Publishing House
EIN Presswire
People’s Medical Publishing House’s Symposium in Beijing discusses the development of high-quality medical journals BEIJING, CHINA, July 21, 2026 /EINPresswire.com/ -- People’s Medical Publishing House organized a symposium on medical journal...
Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
GlobeNewswire, Inc.
Tempest’s TPST-4003 is a next-generation in vivo CAR-T candidate combining proprietary CD7-targeted mRNA/LNP delivery with a dual-target CD19/BCMA CAR construct designed to enable broad B-cell lineage depletion and immune reset for autoimmune and...
PatientsLikeMe and Science 37 Partner to Unlock Trial Access for Interested, Eligible Patients
GlobeNewswire, Inc.
BOSTON and MORRISVILLE, N.C., July 21, 2026 (GLOBE NEWSWIRE) -- PatientsLikeMe (“PLM”) Powered by Fuze Health, a leading patient engagement and health insights platform, and Science 37, the industry-leading patient access company for clinical...
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
GlobeNewswire, Inc.
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4...
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
GlobeNewswire, Inc.
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye...
OKYO Pharma Announces Purchase of Shares by Chairman
GlobeNewswire, Inc.
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye...
Axiom Biosciences Announces Intention to Become the First U.S. Biotech to List on the Hong Kong Stock Exchange
GlobeNewswire, Inc.
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- Axiom Biosciences, a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today announced its intention to pursue an...
Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
GlobeNewswire, Inc.
BOSTON, July 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that...
Vaxart to Participate in BTIG Biotechnology Conference 2026
GlobeNewswire, Inc.
SOUTH SAN FRANCISCO, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that...
Zhengye Biotechnology Holding Limited Comments on Unusual Trading Activity
GlobeNewswire, Inc.
Jilin, China, July 21, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary...
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
GlobeNewswire, Inc.
MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for...
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
GlobeNewswire, Inc.
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers,...
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
GlobeNewswire, Inc.
PolyPid to potentially receive over $320 million in upfront and milestone payments, including $30 million in upfront and near-term milestone payments, plus tiered royalties ranging from mid-teen to mid-twenties percentages Azurity, a private...
Astera Labs Expands Taurus Family with Industry’s First OCP-Standard Footprint Compatible 3.2T Smart Retimers and Smart Redrivers
GlobeNewswire, Inc.
News Highlights: Expanded Taurus family adds 3.2T Ethernet Smart Retimers and Smart Redrivers for scale-up and scale-out AI infrastructure.
Revagenix Expands Executive Team, Names Peter Smith, Ph.D., Chief Scientific Officer as Lead Program Enters the Clinic
GlobeNewswire, Inc.
SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Revagenix, Inc., a biopharmaceutical company developing targeted, purpose-built medicines for serious chronic diseases, today announced the promotion of Peter Smith, Ph.D., to Chief Scientific...
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
GlobeNewswire, Inc.
HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual...
i-Lumen Scientific Announces 1st U.S. Patient Randomized in i-SIGHT2 Pivotal Study for Intermediate to Advanced Dry AMD
EIN Presswire
Milestone initiates U.S. pivotal clinical trial of the i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration BLOOMINGTON, MN, UNITED STATES, July 21, 2026 /EINPresswire.com/ -- i-Lumen Scientific,...
Dragonfly Energy Appoints Transportation Industry Veteran Robert Keller to Lead National Fleet Sales
GlobeNewswire, Inc.
RENO, Nev., July 21, 2026 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and maker of Battle Born Batteries®, today announced that Robert Keller has...
Sign up for:
Technology News Journal
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.